Pernas, S. Et Al. 2024. Fulvestrant with or without the cyclin-dependent kinase 7 (CDK7) inhibitor samuraciclib in advanced hormone receptor positive (HR plus ) breast cancer after CDK4/6 inhibition: Phase II SUMIT-BC study. Special Clinical Science Symposia , (ELECTR NETWORK).

Pernas, S., Hinojo, C., Pascual, J., AKSOY, S., Clack, G., & McIntosh, S., (2024). Fulvestrant with or without the cyclin-dependent kinase 7 (CDK7) inhibitor samuraciclib in advanced hormone receptor positive (HR plus ) breast cancer after CDK4/6 inhibition: Phase II SUMIT-BC study . Special Clinical Science Symposia, ELECTR NETWORK

Pernas, Sonia Et Al. "Fulvestrant with or without the cyclin-dependent kinase 7 (CDK7) inhibitor samuraciclib in advanced hormone receptor positive (HR plus ) breast cancer after CDK4/6 inhibition: Phase II SUMIT-BC study," Special Clinical Science Symposia, ELECTR NETWORK, 2024

Pernas, Sonia Et Al. "Fulvestrant with or without the cyclin-dependent kinase 7 (CDK7) inhibitor samuraciclib in advanced hormone receptor positive (HR plus ) breast cancer after CDK4/6 inhibition: Phase II SUMIT-BC study." Special Clinical Science Symposia , ELECTR NETWORK, 2024

Pernas, S. Et Al. (2024) . "Fulvestrant with or without the cyclin-dependent kinase 7 (CDK7) inhibitor samuraciclib in advanced hormone receptor positive (HR plus ) breast cancer after CDK4/6 inhibition: Phase II SUMIT-BC study." Special Clinical Science Symposia , ELECTR NETWORK.

@conferencepaper{conferencepaper, author={Sonia Pernas Et Al. }, title={Fulvestrant with or without the cyclin-dependent kinase 7 (CDK7) inhibitor samuraciclib in advanced hormone receptor positive (HR plus ) breast cancer after CDK4/6 inhibition: Phase II SUMIT-BC study}, congress name={Special Clinical Science Symposia}, city={}, country={ELECTR NETWORK}, year={2024}}